RAPT THERAPEUTICS INC. - COMMON STOCK

RAPT Therapeutics Reports Third Quarter 2024 Financial Results

12 Nov 2024 07:00:00 By Nasdaq GlobeNewswire

Based on Recent FDA Feedback RAPT Therapeutics Stops Zelnecirnon Program Following Clinical Hold Due to Single SAE of Severe Liver Injury

11 Nov 2024 07:00:00 By Nasdaq GlobeNewswire

RAPT Therapeutics Reports Second Quarter 2024 Financial Results

08 Aug 2024 07:00:00 By Nasdaq GlobeNewswire

RAPT Therapeutics Reports First Quarter 2024 Financial Results

09 May 2024 07:00:01 By Nasdaq GlobeNewswire

RAPT Therapeutics Announces Promising Results from Phase 2 Trial of Tivumecirnon in Combination with Anti-PD-1 Immunotherapy in CPI-Experienced Head and Neck Cancer Patients

09 Apr 2024 11:00:00 By Nasdaq GlobeNewswire

RAPT Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results

07 Mar 2024 07:00:00 By Nasdaq GlobeNewswire

RAPT Therapeutics Announces Multiple Late-Breaking Presentations at the Upcoming American Association for Cancer Research (AACR) Annual Meeting

05 Mar 2024 15:30:00 By Nasdaq GlobeNewswire

RAPT Therapeutics Announces Clinical Hold on Studies Evaluating Zelnecirnon

20 Feb 2024 06:30:00 By Nasdaq GlobeNewswire

RAPT Therapeutics Bolsters Leadership Team with the Appointment of Nipun Davar, Ph.D., as Senior Vice President of Technical Operations

13 Feb 2024 07:00:00 By Nasdaq GlobeNewswire

RAPT Therapeutics to Participate in the Guggenheim Healthcare Talks 6th Annual Biotechnology Conference

31 Jan 2024 07:00:00 By Nasdaq GlobeNewswire

RAPT Therapeutics to Present at the 42nd Annual J.P. Morgan Healthcare Conference

02 Jan 2024 07:00:00 By Nasdaq GlobeNewswire

RAPT Therapeutics Announces Publication of Phase 1a/1b Clinical Trial of Zelnecirnon (RPT193) to Treat Atopic Dermatitis in Allergy

27 Nov 2023 07:00:00 By Nasdaq GlobeNewswire

RAPT Therapeutics Reports Third Quarter 2023 Financial Results

13 Nov 2023 07:00:00 By Nasdaq GlobeNewswire

RAPT Therapeutics Announces Positive Data, Including Objective Response Rates and Progression-Free Survival, from its Phase 2 Trial of FLX475 in Combination with a Checkpoint Inhibitor in Patients with Advanced NSCLC

03 Nov 2023 11:00:00 By Nasdaq GlobeNewswire

RAPT Therapeutics to Participate in Several Upcoming Investor Conferences in November

01 Nov 2023 15:05:00 By Nasdaq GlobeNewswire

RAPT Therapeutics Announces Two FLX475 Presentations at the Society for Immunotherapy of Cancer (SITC) 2023 Annual Meeting

18 Oct 2023 08:00:00 By Nasdaq GlobeNewswire

RAPT Therapeutics to Participate in Several Upcoming Investor Conferences in September

30 Aug 2023 15:05:00 By Nasdaq GlobeNewswire

RAPT Therapeutics Reports Second Quarter 2023 Financial Results

11 Aug 2023 07:00:00 By Nasdaq GlobeNewswire

RAPT Therapeutics to Participate in the Goldman Sachs Global Healthcare Conference

07 Jun 2023 07:00:00 By Nasdaq GlobeNewswire

RAPT Therapeutics to Present Biomarker Data Corroborating Demonstrated Clinical Activity and Mechanism of Action of FLX475 in Advanced Cancers

25 May 2023 16:00:00 By Nasdaq GlobeNewswire